Hibergene has a growing portfolio of molecular diagnostic products for human infectious diseases. Using the proven LAMP (Loop Mediated Isothermal Amplification) technology, the company has developed a range of tests which now includes Meningococcus, Group B Streptococcus and C. Difficile with tests for Mycoplasma Pneumoniae and Flu A/B currently under development. In addition, the company has an active research pipeline and from this expects to launch a number of new tests every year.
Hibergene’s products meet a number of critical criteria for their use in a clinical setting. The tests are:
- Easy to use
- Highly accurate
In addition, they meet a number of significant unmet clinical needs, and can be used in a near patient setting.
Alongside this, Hibergene is developing a global distribution network covering Europe, Middle East, Far East and the USA.
Hibergene is currently supported through a number of institutional investors and private investors from across Ireland and the UK. To find out more, please contact us.